Datasea Inc. announced that it has finished engineering‑stage development of two acoustic‑driven brain‑computer interface (BCI) technologies: a Real‑Time Closed‑Loop Vibration‑Enhanced BCI System and an Acoustic‑Coupled EEG Signal Enhancement System. The completion marks the first time the company has built fully functional prototypes that can decode brain signals in real time, adjust stimulation parameters on the fly, and amplify neural signals using acoustic fields.
The vibration‑enhanced system uses a low‑frequency acoustic field to increase the signal‑to‑noise ratio of EEG recordings, while the coupled system applies acoustic coupling to improve the fidelity of the captured signals. Together, the technologies enable closed‑loop neuromodulation and non‑invasive brain‑computer interaction, opening pathways for applications in neurorehabilitation, assistive devices, and consumer health monitoring.
This milestone aligns with Datasea’s broader strategy to shift from its legacy 5G messaging business to higher‑margin acoustic AI products. The company’s recent quarterly reports show a 25% year‑over‑year rise in revenue driven by its 5G+AI multimodal digital business, yet profitability remains a challenge. By adding a BCI platform that could tap into the projected $15‑$20 billion global BCI market by 2030, Datasea is positioning itself to capture a share of the $1 trillion wearable‑technology market and diversify its revenue streams.
CEO Zhixin Liu emphasized that the BCI development “marks the successful completion of our core EEG technology chain” and signals the company’s readiness to pursue commercialization. While the engineering‑stage milestone does not generate immediate revenue, the company expects to begin regulatory submissions and pilot studies in the next 12‑18 months, with a commercial launch targeted for 2027. The move is intended to accelerate the company’s transition to profitability by leveraging its acoustic physics expertise in a high‑margin, high‑growth segment.
The announcement underscores Datasea’s commitment to investing in breakthrough acoustic technologies and reflects a strategic pivot that could reshape its long‑term growth trajectory. Investors will be watching how quickly the company can move from prototype to marketable product and how it navigates the regulatory landscape for medical devices.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.